• How Kinase Inhibitors Promote p38α Dephosphorylation

  2026-09-27

  The study finds that some p38α inhibitors do more than block kinase activity: they shift the activation loop into conformations that allow the phosphatase WIP1 to remove an activating phosphate more readily. Biochemical and structural results suggest that kinase conformation can influence dephosphorylation, offering a complementary strategy for studying the duration and specificity of kinase inhibition.

• ML385: NRF2 Inhibition for Redox Cancer Studies

  2026-09-26

  Use ML385 to test whether NRF2-dependent stress responses help cancer cells withstand oxidative challenges—not simply to measure cell killing. A practical workflow pairs dose and time titration with pathway readouts, ferroptosis-associated assays, and carefully controlled combination experiments, including exploratory work in pancreatic cancer.

• Tubastatin A: HDAC6 Inhibition in Cardiac Injury

  2026-09-25

  See how Tubastatin A can help researchers connect HDAC6 target engagement with myocardial injury and programmed cell-death readouts. A porcine cardiac-arrest study provides a translational benchmark, while practical workflow guidance highlights controls, assay timing, and common troubleshooting decisions.

• Phenacetin in hiPSC Intestinal Organoid PK Studies

  2026-09-25

  Pair Phenacetin with human iPSC-derived intestinal organoids to investigate compound handling in a model that can develop mature intestinal cell types, drug-metabolizing activity, and transport activity. This workflow distinguishes what the organoid study establishes from practical, experimentally optimized starting conditions for testing Phenacetin.

• UK-5099 in Immunometabolism Assays

  2026-09-24

  Use UK-5099 to test whether mitochondrial pyruvate uptake contributes to stimulus-dependent cytokine responses, while retaining the multicellular context of fresh whole blood. This practical framework separates published whole-blood methods from proposed compound-optimization steps and highlights controls needed to interpret metabolic effects.

• Camostat Mesilate: Applied Research Workflows

  2026-09-24

  Use Camostat Mesilate to probe protease-dependent ENaC regulation and plasmin–TGF-β signaling, with workflows tailored to epithelial and hepatic models. A separate structure-guided antiviral study offers a useful assay-design comparison—not evidence that Camostat blocks the SARS-CoV-2 Spike–ACE2 interaction.

• Anagliptin Vasorelaxation: Kv Channels and SERCA

  2026-09-23

  A 2025 Acta Diabetologica study identified a vascular action of Anagliptin in phenylephrine-contracted rabbit aortic rings that involved voltage-dependent potassium channels and the SERCA pump. The findings provide a pharmacological framework for vasorelaxant mechanism research while indicating that the response was independent of endothelium, cAMP/PKA, and cGMP/PKG signaling in this ex vivo model.

• Dorsomorphin 2HCl: AMPK Workflow Guide

  2026-09-22

  Dorsomorphin 2HCl provides a practical pharmacological challenge for testing whether AMPK activation is causally responsible for metabolic phenotypes. This guide translates a probiotic–alcoholic steatosis study into reproducible formulation, control, readout, and troubleshooting decisions while accounting for the compound’s additional BMP activity.

• Polyethylenimine Linear for Mechanistic Assays

  2026-09-22

  Polyethylenimine Linear (PEI), MW 40,000 supports serum-compatible DNA delivery for transient gene expression, pathway rescue, and recombinant protein production. This guide translates the reagent into a reproducible workflow for mechanistic toxicology assays, including studies of arsenic-associated blood-testis barrier disruption.

• Cathepsin B inhibitor CA-074 Workflow Guide

  2026-09-21

  CA-074 provides a high-affinity, selective tool for testing cathepsin B involvement in proteolysis, cancer metastasis, neurotoxicity, and immune response modulation. It is suitable for controlled biochemical and cell-based experiments, but should not be treated as a broad protease inhibitor or as evidence of clinical efficacy without model-specific validation.

• SAR131675: Selective VEGFR-3 Inhibitor

  2026-09-21

  SAR131675 is a selective, ATP-competitive VEGFR-3 inhibitor for mechanistic studies of lymphangiogenesis, endothelial migration, fibrosis, and tumor biology. Its preclinical profile combines nanomolar VEGFR-3 activity with limited activity against VEGFR-1, VEGFR-2, and broad off-target panels, but development was discontinued because of adverse metabolic effects.

• Conformation-Guided uPAR-uPA Inhibitor Discovery

  2026-09-20

  Khanna and colleagues used molecular-dynamics-derived conformations of uPAR to discover IPR-456, a small molecule that disrupts the difficult uPAR·uPA protein-protein interaction. Biochemical, computational, and breast-cancer cell assays linked receptor binding with reduced uPA engagement and invasion, while the distinct effects on migration and adhesion clarified the selectivity of the mechanism.

• Fungal IAA Drives Ferroptosis in Rice Blast Conidia

  2026-09-19

  A 2026 Molecular Plant Pathology study shows that Magnaporthe oryzae-derived indole-3-acetic acid promotes iron accumulation, lipid peroxidation, and ferroptotic death during conidial development. Mutant analysis and phosphatidylethanolamine rescue experiments connect IAA-dependent lipid metabolism and autophagy with appressorium formation and rice blast pathogenicity.

• BMX-IN-1: A Host-Directed Infection Tool

  2026-09-18

  BMX-IN-1 is a selective BMX kinase inhibitor that connects cancer signaling with host-directed tuberculosis research. This article explains how BMX-dependent ATP6V1E1 phosphorylation can be translated into rigorous target-engagement, lysosomal-function, and macrophage infection assays.

• A-1331852: BCL-XL Inhibitor in Senescence

  2026-09-18

  A-1331852 is a selective BCL-XL inhibitor for dissecting apoptosis in chemotherapy-induced senescent cancer cells. This article connects BCL-XL–BIM complex disruption with assay design, dependency controls, and the translational limits of applying BH3-mimetic evidence across tumor models.

8178 records 1/546 page Next 12345 下5页 Last page